Description
ER-FECAL REPORTABLE TEST-POLYMEDCO
First action · last action
2012-01-25 · 2012-01-25
Transactions
1
First transaction's obligation
$28,980
Base + all options value (sum of deltas)
$28,980
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
—
SDVOSB flag on record
No
Parent IDV
V797P7136A
NAICS
334516 · ANALYTICAL LABORATORY INSTRUMENT MANUFACTURING
Modification chain · 1 transaction
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2012-01-25+$28,980= $28,980
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2012-01-25 | +$28,980 | $28,980 | ER-FECAL REPORTABLE TEST-POLYMEDCO |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI STNDUK44ENE8)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C26226N0941 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $25,596 | FY2026 |
| 36C24726N0361 | 247-NETWORK CONTRACT OFFICE 7 (36C247) · Q403 · MEDICAL- EVALUATION/SCREENING | $90,000 | FY2026 |
| 36C25726N0497 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $30,770 | FY2026 |
| 36C24526N0729 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6630 · CHEMICAL ANALYSIS INSTRUMENTS | $90,000 | FY2026 |
| 36C24526A0052 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6630 · CHEMICAL ANALYSIS INSTRUMENTS | $0 | FY2026 |
| 36C25726N0398 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $68,049 | FY2026 |
Other recipients under Q301 from 552-DAYTON (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA25016P0488 | ATHENA DIAGNOSTICS, INC | 552-DAYTON | $9,999 | FY2016 |
| VA25014F1316 | BIOMERIEUX INC | 552-DAYTON | $6,078 | FY2014 |
| VA25013P1020 | MYRIAD GENETIC LABORATORIES INC | 552-DAYTON | $6,764 | FY2013 |
| VA25013F0126 | GOVERNMENT SCIENTIFIC SOURCE INC | 552-DAYTON | $36,480 | FY2013 |
| VA25012F0125 | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 552-DAYTON | $144,211 | FY2012 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA25012F0499_3600_V797P7136A_3600 · retrieved 2026-09-26.